An evaluation of risk applied to marijuana products for recreational or medical purposes concludes that advanced mitigation strategies and new protective delivery protocols are necessary to adequately protect the public from harm. In Canada a controlled distribution program is in place called the RevAid®.1,2 This program assures consumers are monitored to prevent or minimize major side effects and or reactions. Under this program only prescribers and pharmacists who are registered or patients who are enrolled and who have agreed to meet all the conditions of the program are given access to these drugs.
Cannabidiol (CBD) and cannabidivarin (CBDV) are natural cannabinoids which are consumed in increasing amounts worldwide in cannabis extracts, as they prevent epilepsy, anxiety, and seizures. It was claimed that they may be useful in cancer therapy and have anti-inflammatory properties. Adverse long-term effects of these drugs (induction of cancer and infertility) which are related to damage of the genetic material have not been investigated. Therefore, we studied their DNA-damaging properties in human-derived cell lines under conditions which reflect the exposure of consumers. Both compounds induced DNA damage in single cell gel electrophoresis (SCGE) experiments in a human liver cell line (HepG2) and in buccal-derived cells (TR146) at low levels (≥ 0.2 µM). Results of micronucleus (MN) cytome assays showed that the damage leads to formation of MNi which reflect chromosomal aberrations and leads to nuclear buds and bridges which are a consequence of gene amplifications and dicentric chromosomes. Additional experiments indicate that these effects are caused by oxidative base damage and that liver enzymes (S9) increase the genotoxic activity of both compounds. Our findings show that low concentrations of CBD and CBDV cause damage of the genetic material in human-derived cells. Furthermore, earlier studies showed that they cause chromosomal aberrations and MN in bone marrow of mice. Fixation of damage of the DNA in the form of chromosomal damage is generally considered to be essential in the multistep process of malignancy, therefore the currently available data are indicative for potential carcinogenic properties of the cannabinoids.
PMID: 30341733 DOI: 10.1007/s00204-018-2322-9
Three studies in rodents suggest prenatal exposure to the drug may pose risks for infants
DANA G. SMITH NOVEMBER 18, 2018
This article was originally published by Scientific American.
One recent study revealed that in 2016 7 percent of pregnant women in California used marijuana, with rates as high as 22 percent among teenage mothers. In Colorado 69 percent of dispensariesrecommended the drug to pregnant women to help with morning sickness.
… prenatal drug exposure can be harmful to unborn babies. Previous research has shown infants exposed to cannabis in the womb are 50 percent more likely to have a lower birth weight. Now three new studies presented Tuesday at the Society for Neuroscience annual meeting here suggest prenatal cannabis exposure—at least in rodents—could have serious consequences for fetal brain development.
In one study researchers at Washington State University in Pullman showed rat pups born to mothers exposed to high amounts of cannabis vapor during pregnancy had trouble with cognitive flexibility. Twice a day the scientists filled the pregnant rats’ containers with marijuana vapor from an e-cigarette, elevating levels of the psychoactive chemical THC (tetrahydrocannabinol) in the rats’ blood to roughly the human equivalent of smoking a joint. After the pups grew up the researchers trained them on a task that measured their ability to think flexibly and learn new rules. The young rats first learned to follow a light cue to push one of two levers in order to receive a sugary treat. The next day, pushing only the left lever would deliver the reward, regardless of which side the light had been on.
The rats exposed to cannabis in utero learned the first rule (following the light cue) without a problem, but they took significantly longer to learn the new rule (pushing the left lever) than did rats not exposed to the drug. The cannabis-exposed rats also made many more mistakes on the second day.
In a similar study, scientists at Auburn University in Alabama found rats born to mothers that had been injected with a low, continuous dose of synthetic cannabis during pregnancy were significantly impaired on several different memory tasks involving mazes…“There was a gap in the acquisition of the memory and the consolidation of the memory.”
The young rats whose mothers were dosed with the drug also had abnormalities in the hippocampus, the brain’s primary memory center. Specifically, they had difficulty creating new connections between neurons—the basis for forming new memories. The researchers think the differences in the hippocampus stem from changes in levels of glutamate, the brain’s main excitatory neurochemical involved in learning and memory..
By GUY ADAMS FOR THE DAILY MAIL PUBLISHED: 24 November 2018
Each of the 400 phone calls to the cannabis dispensaries followed a script. ‘Hi,’ said a female voice. ‘I’m eight weeks pregnant and feeling really nauseated. Are there any products recommended for morning sickness?’
In two-thirds of cases, the reply was: ‘Yes’.
Around half of those callers who’d received an affirmative answer were then advised to buy a specific ‘cure’ in a form they could eat.
Just under 40 per cent were told to get it in a form that could be inhaled or smoked. Most of the remainder were offered tinctures or drinks.
The recommended cure in question? Marijuana. But far from being genuine requests for help from expectant mothers, the phone calls were part of a research project by the University of Colorado.
The researchers were pretending to be pregnant to see how cannabis — legal for medical reasons in the U.S. state of Colorado since 2000 and fully legal since 2014 — was being dispensed. The answers they received offer a worrying insight into the booming medical marijuana industry.
‘After eight weeks [of pregnancy], everything should be good with consuming alcohol and weed,’ one dispensary assistant replied.
‘When I was pregnant and started to feel nauseous, I did not smoke [cannabis] more than two times a day,’ recommended the proprietor of another clinic.
‘Edible [marijuana] would not hurt the child,’ reassured another, telling the woman, wrongly, that something ‘going through your digestional tract’ will have no effect on an unborn child.
Of the 277 dispensaries that recommended cannabis as a cure for morning sickness, three-quarters then attempted to sell a version of the drug containing THC, the chemical that gives users a ‘high’.
Many also advised their pregnant patients to keep their consumption of this intoxicating drug secret from their doctor.
‘The doctor will probably just tell you that marijuana is bad for kids and try pushing pills on you,’ said one. ‘I do not know if the baby doctors are chill or not, [so] do not go stoned when you talk to them,’ warned another.
Perhaps those doctors had good reason for their reservations about cannabis. For the Colorado research paper, published in the journal Obstetrics and Gynaecology earlier this year, highlights cannabis as a matter of growing concern to medical practitioners across the world.
Increasingly, marijuana is being sold for medical reasons. Yet this ‘medical’ marijuana is very far from being the safe, natural healthcare product its often-rapacious suppliers would have us believe.
In some circumstances, the product — which is becoming legal in growing numbers of countries, including Canada, the U.S. and most recently Britain in highly specific circumstances — can be dangerous and possibly fatal. Particularly when taken by pregnant women.
To blame is a simple fact: a multitude of studies over several years have shown all forms of cannabis to be ‘teratogenic’. Meaning that, like tobacco or excessive alcohol, they can harm a foetus.
The drug has been linked to a host of serious birth defects, including at least six life-threatening deformities.
They include two congenital heart problems; a neurological condition called anencephaly, in which a child is born with a large portion of the brain missing, often dying within hours; and the birth defect gastroschisis, where the intestines develop outside the body.
‘Babies exposed to marijuana in utero are at increased risk of admission to neonatal intensive care units,’ says Torri Metz, a University of Utah professor who was among the Colorado study’s authors.
‘There are also concerns about possible long-term effects on the developing brain, impacting cognitive function and decreasing academic ability later in childhood.’
Which brings us to the situation in Britain, where there is pressure on the Government from an increasingly powerful cannabis lobby to loosen the NHS guidelines on medical cannabis use.
Med J Aust || doi: 10.5694/mja17.01099 bPublished online: 12 November 2018
Although medicinal cannabis can now be prescribed for CINV, high quality clinical trial evidence is required to determine its efficacy and safety
Access to medicinal cannabis in Australia is a rapidly evolving and controversial field that is relevant to clinicians across a range of medical disciplines. There is widespread community interest in allowing access to medicinal cannabis for a variety of unapproved indications, despite a lack of high level evidence of efficacy.1 Legal and regulatory constraints make this access challenging; however, state and federal governments have now passed legislation enabling prescription by medical practitioners of medicinal cannabis in defined circumstances.2 In recognition of the lack of high level evidence supporting the use of medicinal cannabis for indications including but not limited to cancer pain, refractory paediatric epilepsy and palliative care, combined with the lack of formalised teaching in medical training programs, the Australian Government Therapeutics Goods Administration, in conjunction with state and territory governments, has commissioned a systematic review into the efficacy of medicinal cannabis, and has developed guidance documents for indications in which the evidence base is strongest to assist clinicians in appropriate prescribing of cannabis-based products.3 Despite these initiatives, willingness by medical practitioners to prescribe remains a significant barrier, with only 34 registered prescribers as of 31 July 2018.4
Taking Action - Stopping Ice
United Nations Office of Drugs & Crime: Drug Prevention & Treatment
Medicinal Cannabis –
Access to medicinal Cannabis Products (TGA)
Access to medicinal cannabis products: steps to using access ...
Presentations, Statements & Conference Resources from WFAD 2018 Forum